Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02972034 |
| Title | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Call for Information (Investigational Site 0002) | Grand Rapids | Michigan | 49546 | United States | Details | |
| Call for Information (Investigational Site 0001) | Nashville | Tennessee | 37203 | United States | Details | |
| Merck Canada | Kirkland | Quebec | H9H 4M7 | Canada | Details |